CN104837819B9 - 神经降压肽受体配体 - Google Patents

神经降压肽受体配体 Download PDF

Info

Publication number
CN104837819B9
CN104837819B9 CN201380063364.8A CN201380063364A CN104837819B9 CN 104837819 B9 CN104837819 B9 CN 104837819B9 CN 201380063364 A CN201380063364 A CN 201380063364A CN 104837819 B9 CN104837819 B9 CN 104837819B9
Authority
CN
China
Prior art keywords
compound
formula
radionuclide
acceptor
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380063364.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104837819A (zh
CN104837819B (zh
Inventor
F·欧斯特坎普
C·斯莫灵
U·莱恩科
C·哈斯
J·翁格威斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3B Pharmaceuticals GmbH
Original Assignee
3B Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals GmbH filed Critical 3B Pharmaceuticals GmbH
Priority to CN201811305966.0A priority Critical patent/CN109320502B/zh
Publication of CN104837819A publication Critical patent/CN104837819A/zh
Application granted granted Critical
Publication of CN104837819B publication Critical patent/CN104837819B/zh
Publication of CN104837819B9 publication Critical patent/CN104837819B9/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380063364.8A 2012-12-07 2013-12-06 神经降压肽受体配体 Active CN104837819B9 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811305966.0A CN109320502B (zh) 2012-12-07 2013-12-06 神经降压肽受体配体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12008208.6A EP2740726A1 (en) 2012-12-07 2012-12-07 Neurotensin receptor ligands
EP12008208.6 2012-12-07
PCT/EP2013/003700 WO2014086499A1 (en) 2012-12-07 2013-12-06 Neurotensin receptor ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811305966.0A Division CN109320502B (zh) 2012-12-07 2013-12-06 神经降压肽受体配体

Publications (3)

Publication Number Publication Date
CN104837819A CN104837819A (zh) 2015-08-12
CN104837819B CN104837819B (zh) 2018-12-07
CN104837819B9 true CN104837819B9 (zh) 2019-07-09

Family

ID=47355771

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380063364.8A Active CN104837819B9 (zh) 2012-12-07 2013-12-06 神经降压肽受体配体
CN201811305966.0A Active CN109320502B (zh) 2012-12-07 2013-12-06 神经降压肽受体配体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811305966.0A Active CN109320502B (zh) 2012-12-07 2013-12-06 神经降压肽受体配体

Country Status (20)

Country Link
US (3) US10961199B2 (enExample)
EP (3) EP2740726A1 (enExample)
JP (2) JP6576828B2 (enExample)
KR (1) KR102290803B1 (enExample)
CN (2) CN104837819B9 (enExample)
AU (1) AU2013354422B2 (enExample)
BR (1) BR112015012530B1 (enExample)
CA (1) CA2893605C (enExample)
DK (2) DK3712131T3 (enExample)
ES (2) ES2795923T3 (enExample)
FI (1) FI3712131T3 (enExample)
HU (2) HUE061839T2 (enExample)
IL (1) IL239080B (enExample)
MX (1) MX370354B (enExample)
PL (2) PL3712131T3 (enExample)
PT (2) PT2928870T (enExample)
RU (1) RU2671970C2 (enExample)
SG (2) SG11201503880YA (enExample)
WO (1) WO2014086499A1 (enExample)
ZA (1) ZA201503446B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP2954934A1 (en) * 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
CA2949936C (en) 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
PT3380495T (pt) 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
CN110997013B (zh) 2017-07-24 2022-09-20 瑞泽恩制药公司 抗cd8抗体和其用途
PL3997103T3 (pl) * 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
US20230390426A1 (en) * 2020-10-22 2023-12-07 Nihon Medi-Physics Co., Ltd. Method for producing radioactive zirconium complex
EP4326344A4 (en) * 2021-04-23 2025-05-07 Fusion Pharmaceuticals Inc. Methods for treatment of cancers
CN117957214A (zh) * 2021-05-13 2024-04-30 总医院公司 用于醛类的体内检测的分子探针
EP4355325A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION OF A NEUROTENSIN RECEPTOR-BINDING COMPOUND AND FOLFIRINOX
EP4355317A4 (en) * 2021-06-16 2025-04-30 Fusion Pharmaceuticals Inc. COMBINATION WITH A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX
EP4355377A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND, GEMCITABINE AND NAB-PACLITAXEL
JP2025503213A (ja) * 2022-01-28 2025-01-30 フュージョン ファーマシューティカルズ インコーポレイテッド Ｎｔｓｒ１標的化放射性医薬品およびチェックポイント阻害剤併用療法
WO2023158802A1 (en) * 2022-02-18 2023-08-24 Full-Life Technologies U.S. Inc. Compounds and radioligands for targeting neurotensin receptor and uses thereof
CN119325393A (zh) * 2022-05-03 2025-01-17 北卡罗来纳大学教堂山分校 用于成像和治疗应用的靶向ntsr的试剂的开发
US12091454B2 (en) 2022-12-28 2024-09-17 Development Center For Biotechnology Humanized anti-human neurotensin receptor 1 antibodies and their uses
IL330349A (en) * 2023-12-28 2026-08-01 Radionetics Oncology Inc Neuropeptide Y1 receptor (NPY1R) targeted therapies and their uses
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607958A (en) * 1990-08-20 1997-03-04 Sanofi 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them
CN1184469A (zh) * 1995-04-11 1998-06-10 萨诺费公司 对神经紧张素受体有活性的1－苯基－3－吡唑甲酰胺类化合物
WO1998033531A1 (en) * 1997-02-03 1998-08-06 Mallinckrodt Medical, Inc. Method for the detection and localization of malignant human tumours
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
US4439359A (en) 1982-07-02 1984-03-27 Merck & Co., Inc. Cyclic octapeptide analogs of neurotensin
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2086453A1 (en) 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
EP0752873A4 (en) 1994-02-18 2002-05-15 Mallinckrodt Inc MARKED PEPTIDE COMPOUNDS
US6054557A (en) 1995-04-04 2000-04-25 Advanced Bioconcept (1994) Ltd. Fluorescent peptides
EP0820466A2 (en) 1995-04-04 1998-01-28 Advanced Bioconcept Inc. Fluorescent peptides
AU6352296A (en) 1995-07-20 1997-02-18 Advanced Bioconcept, Inc. Cell sorting with fluorescent peptides
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6214790B1 (en) 1998-04-10 2001-04-10 Mayo Foundation For Medical Education And Research Neo-tryptophan
AU6338000A (en) 1999-06-24 2001-01-09 Jack L. Erion Labeled neurotensin derivatives
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
JP5592377B2 (ja) * 2008-09-16 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 放射能標識のための［１８ｆ］ｓｆｂの単純化ワンポット合成
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
ES2538002T3 (es) * 2009-01-07 2015-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama
US9809624B2 (en) 2009-07-16 2017-11-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607958A (en) * 1990-08-20 1997-03-04 Sanofi 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them
CN1184469A (zh) * 1995-04-11 1998-06-10 萨诺费公司 对神经紧张素受体有活性的1－苯基－3－吡唑甲酰胺类化合物
WO1998033531A1 (en) * 1997-02-03 1998-08-06 Mallinckrodt Medical, Inc. Method for the detection and localization of malignant human tumours
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Also Published As

Publication number Publication date
SG11201503880YA (en) 2015-06-29
WO2014086499A1 (en) 2014-06-12
US10961199B2 (en) 2021-03-30
CN104837819A (zh) 2015-08-12
FI3712131T3 (fi) 2023-03-28
RU2671970C2 (ru) 2018-11-08
PT3712131T (pt) 2023-04-04
AU2013354422A1 (en) 2015-05-28
IL239080B (en) 2019-06-30
EP3712131B1 (en) 2023-02-01
ZA201503446B (en) 2016-01-27
US20150299133A1 (en) 2015-10-22
DK2928870T3 (da) 2020-07-13
PT2928870T (pt) 2020-05-29
BR112015012530B1 (pt) 2022-07-19
CA2893605C (en) 2021-08-10
JP6576828B2 (ja) 2019-09-18
HUE061839T2 (hu) 2023-08-28
IL239080A0 (en) 2015-07-30
DK3712131T3 (da) 2023-03-20
PL2928870T3 (pl) 2020-09-21
EP3712131A1 (en) 2020-09-23
MX2015007193A (es) 2016-03-17
SG10201704564QA (en) 2017-07-28
CN109320502B (zh) 2022-06-07
JP7042776B2 (ja) 2022-03-28
ES2941629T3 (es) 2023-05-24
EP2740726A1 (en) 2014-06-11
US20210087149A1 (en) 2021-03-25
CN104837819B (zh) 2018-12-07
CN109320502A (zh) 2019-02-12
EP2928870B1 (en) 2020-04-08
WO2014086499A8 (en) 2014-12-31
KR20150092300A (ko) 2015-08-12
PL3712131T3 (pl) 2023-05-02
AU2013354422B2 (en) 2018-03-15
HUE050388T2 (hu) 2020-11-30
JP2019218375A (ja) 2019-12-26
BR112015012530A2 (pt) 2017-09-12
KR102290803B1 (ko) 2021-08-18
EP2928870A1 (en) 2015-10-14
RU2015127086A (ru) 2017-01-11
JP2016501238A (ja) 2016-01-18
ES2795923T3 (es) 2020-11-25
HK1210148A1 (en) 2016-04-15
CA2893605A1 (en) 2014-06-12
US20260078095A1 (en) 2026-03-19
MX370354B (es) 2019-12-10

Similar Documents

Publication Publication Date Title
US20260078095A1 (en) Neurotensin receptor ligands
JP7065567B2 (ja) ニューロテンシン受容体リガンドを含むコンジュゲートおよびそれらの使用
Nock et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study
Alshoukr et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors
US20210402016A1 (en) Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
Shi et al. 99mTc-labeled bombesin (7− 14) NH2 with favorable properties for SPECT imaging of colon cancer
Kanellopoulos et al. Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology
Varshney et al. 68Ga-labeled bombesin analogs for receptor-mediated imaging
KR20250016195A (ko) 전립선-특이적 막 항원(psma) 리간드
HK40003630A (en) Neurotensin receptor ligands
HK40003630B (en) Neurotensin receptor ligands
HK40037865A (en) Neurotensin receptor ligands
HK40037865B (en) Neurotensin receptor ligands
HK1210148B (en) Neurotensin receptor ligands
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
Mascarin Triazole-Based Radiopeptidomimetics: Novel Neurotensin (8-13) Analogues with Increased Metabolic Stability

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CI03 Correction of invention patent
CI03 Correction of invention patent

Correction item: Claims

Correct: Zheng Que

False: Error

Number: 49-02

Page: full text

Volume: 34